• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Emergent BioSolutions Inc.

    11/13/24 4:00:18 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email
    SC 13G 1 p24-3235sc13g.htm EMERGENT BIOSOLUTIONS INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No.)*
     

    Emergent BioSolutions Inc.

    (Name of Issuer)
     

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    29089Q105

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 29089Q10513GPage 2 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

    Oak Hill Advisors, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    3,613,338 shares of Common Stock (including 2,500,000 shares of Common Stock issuable upon exercise of warrants)

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    3,613,338 shares of Common Stock (including 2,500,000 shares of Common Stock issuable upon exercise of warrants)

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,613,338 shares of Common Stock (including 2,500,000 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.39%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 29089Q10513GPage 3 of 6 Pages

     

     

    Item 1(a). NAME OF ISSUER:
       
     

    Emergent BioSolutions Inc. (the “Company”)

       
    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      300 Professional Drive, Gaithersburg, MD 20879.
       
    Item 2(a). NAME OF PERSON FILING:
       
      This Schedule 13G is being filed on behalf of Oak Hill Advisors, L.P., a Delaware limited partnership (“OHA” or, the “Reporting Person”), as investment adviser to certain funds and client accounts (directly or through an affiliate) (together, the “Oak Hill Funds”), with respect to the shares of Common Stock and the shares of  Common Stock issuable upon exercise of warrants directly held by the Oak Hill Funds.
       
      OHA is a subsidiary business of T. Rowe Price Associates, Inc. (“TRP”).  OHA’s beneficial ownership does not include any shares that may be beneficially owned by TRP.
       
      Glenn R. August, a United States citizen, is the Founder and Chief Executive Officer of OHA.
       
      Any disclosures herein with respect to persons other than the Reporting Person are made on information and belief after making inquiry to the appropriate party.  The filing of this statement should not be construed in and of itself as an admission by the Reporting Person as to beneficial ownership of the securities reported herein.
       
    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of the Reporting Person is One Vanderbilt Avenue, 16th Floor, New York, New York 10017.
       
    Item 2(c). CITIZENSHIP:
       
      OHA is a Delaware limited partnership.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the “Common Stock”)

     

    Item 2(e). CUSIP NUMBER:
       
      29089Q105

     

     

    CUSIP No. 29089Q10513GPage 4 of 6 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:______________________________

     

    Item 4. OWNERSHIP:
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.
       
      The percentage set forth in Row 11 of the cover page for the Reporting Person is calculated based upon 54,019,962 shares of  Common Stock, which is the sum of (i) 52,906,624 shares of Common Stock outstanding as of July 30, 2024, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 7, 2024 and (ii) 1,113,338 shares of Common Stock issued by the Company on September 17, 2024, as disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2024, and assumes the exercise of warrants reported herein.

     

    CUSIP No. 29089Q10513GPage 5 of 6 Pages

     

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2. The Oak Hill Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:
       
      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         

     

     

    CUSIP No. 29089Q10513GPage 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 13, 2024

     

    oak hill advisors, l.p.  
       
    By: /s/ Gregory S. Rubin  
    Name: Gregory S. Rubin  
    Title: Authorized Signatory  
         
         

     

    Get the next $EBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      5/15/25 4:02:40 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

      GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS) for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT®, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pedi

      6/23/25 8:05:07 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Announces Addition to Russell 3000® Index

      GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes. "Inclusion in the Russell 3000® Index is an important milestone in Emergent's ongoing transformation," said Joe Papa, president and chief executive officer of Emergent BioSolutions. "This recognition reflects the positive momentum we are building across the organization and helps to position us to enter a new phase of disciplined, sustainable growth in the year ahead. It also reaffirms our c

      6/20/25 8:13:29 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

      Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) is teaming up with Victoria's Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victoria's Voice has launched the "Shine. Wear. Share. Care" campaign to raise awareness and provide educational resources to individuals, organizations and businesses that includes a purple

      6/5/25 7:00:21 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

      H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

      12/30/24 7:24:57 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

      Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

      8/22/24 7:22:39 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00

      3/7/24 10:14:18 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 1,249 shares, decreasing direct ownership by 0.71% to 174,927 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:36 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Bioservices Hartzel William covered exercise/tax liability with 1,167 shares, decreasing direct ownership by 1% to 107,955 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:45 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Products Business Williams Paul Anthony covered exercise/tax liability with 464 shares, decreasing direct ownership by 0.54% to 85,871 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:27 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    SEC Filings

    See more
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      6/24/25 4:09:39 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      5/23/25 4:06:03 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Emergent BioSolutions Inc.

      144 - Emergent BioSolutions Inc. (0001367644) (Subject)

      5/23/25 4:04:26 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care